This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: All You Need to Know About Hep C Drugs

The "new" Agenus investor story is QS-21, an adjuvant added to vaccines to boost immune response. Agenus shares have soared to more than $6 from $2 at the beginning of the year, mainly because of hype around QS-21 and its inclusion in 15 vaccines under clinical development. Most notable are three GlaxoSmithKline (GSK) vaccines or immunotherapies in late-stage clinical trials for malaria, non-small cell lung cancer and melanoma; all contain Agenus' QS-21.

Agenus' stock really took off in early March after the company announced an amended QS-21 agreement with Glaxo, giving the latter "first right to negotiate for the purchase of the company or certain of our assets," according to an Agenus regulatory filing.

Naturally, buzz among retail investors reached a fever pitch on empty speculation that Glaxo was going to buy Agenus. The deal hasn't happened yet, and I have doubts it will ever take place. Without the takeover buzz, Agenus is overvalued.

Glaxo is obligated to pay a mid-single-digit royalty to Agenus on sales of any QS-21-containing vaccine/immunotherapy that is approved and marketed. Glaxo's malaria vaccine looks to be effective but the company has already stated that it will be giving it away. [Malaria is a problem in Africa, not so much in the U.S. or Europe.] Results from late-stage studies of Glaxo's melanoma and lung cancer immunotherapies have not been released.

Why would Glaxo buy Agenus, presumably at a premium to its current $145 million market value, when it can more cheaply pay a 5% royalty on sales of products? Doesn't make much sense to me, although I admit Glaxo has a history of making stupid acquisitions -- the $700 million spent to buy Sirtris comes to mind.

Agenus' patent to purified QS-21 expired in 2008 and other vaccine adjuvants, including those similar to QS-21, are already in clinical development. Glaxo even has its own adjuvant known as MPL under development. These competitors raise questions about the long-term future of QS-21.

Here's what I'd like to see happen with Agenus, given the company's long history of drug-development futility: Link founder and CEO Garo Armen's compensation to QS-21 royalties. Right now, Armen makes $464,000 a year -- an outrageously high salary for a guy responsible for a minus 70% shareholder return over the past five years. [Agenus, formerly Antigenics, has shed 97% of its value since 2000.]
4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AGEN $9.16 6.40%
BMY $67.53 0.07%
CLDX $25.50 4.70%
GILD $115.59 0.48%
AAPL $126.00 -0.35%

Markets

DOW 17,683.58 -46.53 -0.26%
S&P 500 2,068.76 -8.02 -0.39%
NASDAQ 4,991.94 -17.2740 -0.34%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs